医薬品開発業務受託機関(CRO)サービスの世界市場予測(~2029):種類別、治療領域別

■ 英語タイトル:Contract Research Organization (CROs) Services Market by Type (Early Phase, Clinical, Lab, Consulting, Data Management), Therapeutic Area (Cancer, Infectious Disease, Neurology, Dermatology, Immunology, Hematology, Vaccines, CGT) - Global Forecast to 2029

調査会社MarketsandMarkets社が発行したリサーチレポート(データ管理コード:PH4672-24)■ 発行会社/調査会社:MarketsandMarkets
■ 商品コード:PH4672-24
■ 発行日:2024年1月22日
■ 調査対象地域:グローバル
■ 産業分野:医薬品
■ ページ数:483
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後24時間以内)
■ 販売価格オプション(消費税別)
Single User(1名様閲覧)USD7,150 ⇒換算¥1,058,200見積依頼/購入/質問フォーム
Multi User (Five User)USD8,500 ⇒換算¥1,258,000見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD9,650 ⇒換算¥1,428,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[医薬品開発業務受託機関(CRO)サービスの世界市場予測(~2029):種類別、治療領域別]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

“医薬品開発業務受託機関(CRO)サービス市場は、予測期間中の年平均成長率9.6%で、2024年の推定820億米ドルから2029年には1,298億米ドルに達すると予測”CROサービス市場の成長を促進する主な要因としては、新薬開発への取り組みの増加が挙げられます。さらに、精密な個別化医薬品に対する需要の高まりは、この市場の機会領域となっています。
CROサービス市場は、タイプ、治療分野、エンドユーザー、地域によって区分されています。

“タイプ別では、早期開発サービス分野がCROサービス市場で第2位のシェアを占める”
タイプ別では、CROサービス市場は、臨床研究サービス、初期開発サービス、ラボサービス、コンサルティングサービス、データマネジメントサービスに分類されます。2023年において、早期開発サービスが同市場で第2位のシェアを占めています。これは、早期開発のさまざまな段階(探索、前臨床)におけるプロセスで発生するコストの増加や関連する厳しい規制要件などの主な要因によるものです。

“エンドユーザー別では、製薬会社・バイオ製薬会社がCROサービス市場で最大のシェアを占める”
エンドユーザーに基づき、CROサービス市場は製薬・バイオ医薬品企業、医療機器企業、学術機関に区分されます。2023年には、製薬・バイオ製薬企業セグメントがCROサービス市場で最大のシェアを占めました。この市場セグメントの大きなシェアは、製薬・バイオテクノロジー企業の医薬品パイプラインの数が多いこと、医薬品開発の分野に進出している製薬・バイオテクノロジー企業の数が多いことに起因しています。

“北米:CROサービス市場で最大シェア”
2023年のCROサービス市場で最大のシェアを占めたのは北米。北米地域の大きなシェアは、医薬品の研究開発に携わる主要な製薬企業やバイオテクノロジー企業の存在という大きな要因によるものです。その結果、同地域では臨床研究活動のアウトソーシングが増加しました。さらに、この地域には確立された医療制度があり、資金や投資を通じてこの市場の成長をさらに後押ししています。

“アジア太平洋: CROサービス市場で最も急成長している地域”
アジア太平洋のCROサービス市場は、予測期間中に最も高いCAGRで成長すると予測されています。これは、臨床試験の実施に必要な多様性とともに、利用可能な患者数が多いことが主な要因の1つです。さらに、同地域では全体的な運営コストが比較的低いため、同地域で臨床試験を実施する組織が集まっています。

本レポートのために実施した主なインタビューは以下のように分類されます:

- 回答者別 供給側:70%、需要側:30%
- 役職別 マネージャー:45%、ディレクター:30%、エグゼクティブ:25%
- 国別 北米:35%、ヨーロッパ:30%、アジア太平洋:25%、中南米:5%、中東・アフリカ:5%

著名プレイヤー

• IQVIA Inc. (US)
• Laboratory Corporation of America Holdings (LabCorp) (US)
• Thermo Fisher Scientific Inc. (US)
• Syneos Health (US)
• WuXi AppTec (China)
• Charles River Laboratories (US)
• Parexel International Corporation (US)
• Pharmaron (China)
• ICON Plc (Ireland)
• Medpace (US)
• SGS SA (Switzerland)
• Frontage Labs (US)
• Eurofins Scientific (Luxembourg)
• PSI CRO AG (Switzerland)
• BioAgile (India)
• Firma Clinical Research (US)
• Acculab Life Sciences (US)
• Novotech (Australia)
• KCR S.A. (US)
• Linical (Japan)
• Advanced Clinical (US)
• Allucent (US)
• Clinical Trial Service (Netherlands)
• Guires Inc. (Pepgra Healthcare Pvt. Ltd.) (UK)
• Worldwide Clinical Trials (US)
• CTI Clinical Trial And Consulting (US)

調査範囲

本レポートはCROサービス市場の詳細な情報を提供します。種類、治療分野、エンドユーザー、地域(北米、ヨーロッパ、アジア太平洋、中南米、中東、アフリカ)など、さまざまなセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの企業プロフィール、最近の動向、主要市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点

本レポートは、CROサービス市場およびそのセグメントにおける収益数の最も近い概算値を提供することで、市場リーダーや新規参入者を支援します。また、利害関係者が競合状況をより良く理解し、より多くの洞察を得ることで、自社のビジネスをより良く位置づけ、適切な市場参入戦略を立てるのに役立ちます。本レポートは、関係者が市場の鼓動を理解し、主要な市場促進要因、機会、課題、動向に関する情報を提供することを可能にします。

本レポートは以下のポイントに関する洞察を提供します:

- CROサービス市場の成長に影響を与える主な促進要因(パイプライン製品数の増加)、機会(個別化医療への注力)、課題(患者募集)、動向(実世界データと実世界エビデンス)の分析しました。
- 市場開発: 有利な市場に関する包括的な情報-本レポートでは、さまざまな地域のCROサービス市場を分析しています。
- 市場の多様化: CROサービス市場における新規サービス、未開拓の地域、最近の開発、投資に関する詳細な情報を記載しています。
- 競合評価:医薬品開発業務受託機関(CRO)サービス市場における、IQVIA Inc. (US), Laboratory Corporation of America Holdings (US), Thermo Fisher Scientific Inc. (US), ICON Plc (Ireland), WuXi AppTec (China), Syneos Health (US), Charles River Laboratories (US), Fortrea, Inc. (US), Pharmaron (China), Eurofins Scientific (Luxembourg) and Medpace (US)などの主要企業の市場シェア、成長戦略、サービス提供の詳細な評価を提供しています。

1. 序論
2. 調査方法
3. エグゼクティブサマリー
4. プレミアムインサイト
5. 市場概要
6. 世界の医薬品開発業務受託機関(CRO)サービス市場規模:種類別
7. 世界の医薬品開発業務受託機関(CRO)サービス市場規模:治療領域別
8. 世界の医薬品開発業務受託機関(CRO)サービス市場規模:エンドユーザー別
9. 世界の医薬品開発業務受託機関(CRO)サービス市場規模:地域別
10. 競争状況
11. 企業情報
12. 付録

*** レポート目次(コンテンツ)***

1 INTRODUCTION (Page No. – 66)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS & EXCLUSIONS
1.4 MARKET SCOPE
1.4.1 MARKETS CONSIDERED
1.4.2 REGIONS CONSIDERED
1.4.3 YEARS CONSIDERED
1.4.4 CURRENCY CONSIDERED
1.5 RESEARCH LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.7.1 RECESSION IMPACT: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET PREDICTION

2 RESEARCH METHODOLOGY (Page No. – 71)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
FIGURE 2 SECONDARY DATA SOURCES
2.1.2 PRIMARY DATA
FIGURE 3 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023
FIGURE 6 ILLUSTRATIVE EXAMPLE OF IQVIA INC.: REVENUE SHARE ANALYSIS, 2023
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
2.2.1 MARKET SIZE ASSESSMENT AT SEGMENTAL LEVEL
FIGURE 8 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
2.3 MARKET GROWTH FORECAST
FIGURE 9 CAGR PROJECTIONS, 2024–2029
FIGURE 10 GROWTH ANALYSIS OF DRIVERS, OPPORTUNITIES, AND CHALLENGES IN CRO SERVICES MARKET
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 11 DATA TRIANGULATION METHODOLOGY
2.5 STUDY ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 IMPACT OF ECONOMIC RECESSION ON MARKET
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2021–2028 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION)

3 EXECUTIVE SUMMARY (Page No. – 83)
FIGURE 12 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET PREDICTION, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 13 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION)
FIGURE 14 MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF CONTRACT RESEARCH ORGANIZATION SERVICES MARKET

4 PREMIUM INSIGHTS (Page No. – 87)
4.1 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET OVERVIEW
FIGURE 16 INCREASING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET
4.2 NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY AND TYPE, 2023
FIGURE 17 US AND CLINICAL RESEARCH SERVICES TO DOMINATE NORTH AMERICAN MARKET IN 2023
4.3 MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 18 CLINICAL RESEARCH SERVICES TO DOMINATE MARKET DURING STUDY PERIOD
4.4 MARKET, BY END USER, 2023
FIGURE 19 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
4.5 GEOGRAPHICAL GROWTH OPPORTUNITIES IN CONTRACT RESEARCH ORGANIZATION SERVICES MARKET
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. – 91)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 DRIVERS, OPPORTUNITIES, AND CHALLENGES: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET PREDICTION
TABLE 4 IMPACT ANALYSIS: CRO SERVICES MARKET
5.2.1 DRIVERS
5.2.1.1 Rising pharmaceutical R&D expenditure and increasing drug pipeline
FIGURE 22 LARGE PHARMACEUTICAL R&D SPENDING (AS A PERCENTAGE OF SALES), 2013–2022
FIGURE 23 ACTIVE PHARMACEUTICAL PIPELINE, 2012–2023
5.2.1.2 Technological advancements in clinical trials and innovative trial designs
5.2.1.3 High cost of in-house drug development
5.2.2 OPPORTUNITIES
5.2.2.1 Favorable growth prospects for biologics and biosimilars market
FIGURE 24 BIOSIMILARS APPROVALS AND LAUNCHES, 2015–2022
5.2.2.2 Need for novel clinical trial designs for complex cell & gene therapies
FIGURE 25 ONGOING CLINICAL TRIALS BY PHASE AND THERAPEUTIC APPROACH (AS OF APRIL 2023)
FIGURE 26 GENE & CELL THERAPY DEVELOPERS, CLINICAL TRIALS, AND INVESTMENT, BY REGION, 2022
5.2.2.3 Emergence of hybrid models with CRO-CDMO partnerships
5.2.2.4 Growing focus on personalized/precision medicine
5.2.2.5 Development of next-generation biotherapeutic products
5.2.3 CHALLENGES
5.2.3.1 Lack of adequate patient recruitment and retention for clinical trials
5.2.3.2 Changing clinical trial complexities
5.3 MARKET TRENDS
5.3.1 INDUSTRY CONSOLIDATION
TABLE 5 LIST OF MERGERS AND ACQUISITIONS
5.3.2 DECENTRALIZED CLINICAL TRIALS
5.3.3 REAL-WORLD DATA AND REAL-WORLD EVIDENCE
5.3.4 INCREASING INVOLVEMENT OF ARTIFICIAL INTELLIGENCE
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 27 REVENUE SHIFT AND NEW POCKETS FOR CRO SERVICE PROVIDERS
5.5 PRICING ANALYSIS
TABLE 6 PRICING ILLUSTRATION FOR FIRST IN-HUMAN TRIAL IN HEALTHY VOLUNTEERS IN EUROPE
5.6 VALUE CHAIN ANALYSIS
FIGURE 28 VALUE CHAIN ANALYSIS: CLINICAL RESEARCH TO ADD MAXIMUM VALUE
5.7 ECOSYSTEM ANALYSIS
TABLE 7 ROLE IN ECOSYSTEM: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET PREDICTION
5.8 TECHNOLOGY ANALYSIS
5.9 CASE STUDY ANALYSIS
5.9.1 PPD TO LEVERAGE ITS PRECLARUS TECHNOLOGY FOR GENERATING CLEANER DATA, FASTER CLINICAL TRIALS, AND LESSER SITE BURDEN
5.9.2 IQVIA TO OFFER AI-POWERED MODELING FOR BETTER PATIENT IDENTIFICATION
5.9.3 USE OF LAB DATA INSIGHTS TO IMPROVE POPULATION MANAGEMENT OF CHRONIC KIDNEY DISEASES
5.9.4 IQVIA TO LEVERAGE ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR IMPROVED SERVICE OFFERINGS
5.10 KEY CONFERENCES & EVENTS
TABLE 8 DETAILED LIST OF KEY CONFERENCES & EVENTS, 2024
5.11 REGULATORY ANALYSIS
5.11.1 REGULATORY ANALYSIS
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11.3 REGULATORY SCENARIO FOR DRUG APPROVALS AND CGMP PROCEDURES
5.12 PORTER’S FIVE FORCES ANALYSIS
TABLE 13 PORTER’S FIVE FORCES ANALYSIS: MARKET
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF BUYERS
5.12.4 BARGAINING POWER OF SUPPLIERS
5.12.5 INTENSITY OF COMPETITIVE RIVALRY
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CRO SERVICES IN PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
5.13.2 BUYING CRITERIA
FIGURE 30 KEY BUYING CRITERIA FOR END USERS

6 CRO SERVICES MARKET, BY TYPE (Page No. – 122)
6.1 INTRODUCTION
TABLE 14 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET PREDICTION, BY TYPE, 2022–2029 (USD MILLION)
6.2 CLINICAL RESEARCH SERVICES
TABLE 15 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES, BY LOCATION (AS OF DECEMBER 21, 2023)
FIGURE 31 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2022 VS. 2023
TABLE 16 EXAMPLES OF CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS
TABLE 17 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 18 CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY REGION, 2022–2029 (USD MILLION)
TABLE 19 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 20 EUROPE: MARKET FOR CLINICAL RESEARCH SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 21 ASIA PACIFIC: MARKET FOR CLINICAL RESEARCH SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 22 LATIN AMERICA: MARKET FOR CLINICAL RESEARCH SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA: MARKET FOR CLINICAL RESEARCH SERVICES, BY REGION, 2022–2029 (USD MILLION)
6.2.1 CLINICAL TRIAL SERVICES MARKET, BY PHASE
6.2.2 PHASE III CLINICAL RESEARCH SERVICES
6.2.2.1 Increased use of clinical resources and advanced technologies to drive segment
TABLE 24 EXAMPLES OF DRUGS IN PHASE III OF CLINICAL TRIALS, 2023
TABLE 25 PHASE III CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 26 NORTH AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 27 EUROPE: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 28 ASIA PACIFIC: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 29 LATIN AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.3 PHASE II CLINICAL RESEARCH SERVICES
6.2.3.1 Rising number of pipeline products to propel market
TABLE 31 EXAMPLES OF DRUGS IN PHASE II OF CLINICAL TRIALS, 2023
TABLE 32 PHASE II CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 33 NORTH AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 34 EUROPE: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 35 ASIA PACIFIC: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 36 LATIN AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.4 PHASE I CLINICAL RESEARCH SERVICES
6.2.4.1 Growing R&D pipeline of pharmaceutical companies to support segment
TABLE 38 EXAMPLES OF DRUGS IN PHASE I OF CLINICAL TRIALS, 2023
TABLE 39 PHASE I CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 40 NORTH AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 41 EUROPE: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 42 ASIA PACIFIC: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 43 LATIN AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.5 PHASE IV CLINICAL RESEARCH SERVICES
6.2.5.1 Increasing number of CROs providing post-marketing surveillance to drive segment
TABLE 45 EXAMPLES OF DRUGS IN PHASE IV OF CLINICAL TRIALS, 2023
TABLE 46 PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 47 NORTH AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 48 EUROPE: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 49 ASIA PACIFIC: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 50 LATIN AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.6 CLINICAL RESEARCH SERVICES MARKET, BY STUDY DESIGN
TABLE 52 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY STUDY DESIGN, 2022–2029 (USD MILLION)
TABLE 53 CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY REGION, 2022–2029 (USD MILLION)
6.2.6.1 Interventional studies
6.2.6.1.1 Better monitoring and data collection with structured protocol to propel segment
TABLE 54 INTERVENTIONAL STUDIES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.6.2 Real world evidence studies
6.2.6.2.1 Increasing focus on informed healthcare decision-making to boost segment
TABLE 55 REAL WORLD EVIDENCE STUDIES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3 EARLY-PHASE DEVELOPMENT SERVICES
TABLE 56 EXAMPLES OF EARLY-PHASE DEVELOPMENT SERVICES OFFERED BY MARKET PLAYERS
TABLE 57 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 58 CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY REGION, 2022–2029 (USD MILLION)
TABLE 59 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 60 EUROPE: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 61 ASIA PACIFIC: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 62 LATIN AMERICA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 63 MIDDLE EAST & AFRICA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY REGION, 2022–2029 (USD MILLION)
6.3.1 CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES
6.3.1.1 Growing need to meet regulatory norms in drug development to drive segment
TABLE 64 CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 65 NORTH AMERICA: CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 66 EUROPE: CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 67 ASIA PACIFIC: CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 68 LATIN AMERICA: CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 69 MIDDLE EAST & AFRICA: CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.2 PRECLINICAL SERVICES
TABLE 70 PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 71 PRECLINICAL SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 72 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 73 EUROPE: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 74 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 75 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 76 MIDDLE EAST & AFRICA: PRECLINICAL SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.2.1 Pharmacokinetics/Pharmacodynamics
6.3.2.1.1 High significance of drug metabolism studies to drive segment
TABLE 77 PHARMACOKINETICS/PHARMACODYNAMICS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 78 NORTH AMERICA: PHARMACOKINETICS/PHARMACODYNAMICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 79 EUROPE: PHARMACOKINETICS/PHARMACODYNAMICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 80 ASIA PACIFIC: PHARMACOKINETICS/PHARMACODYNAMICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 81 LATIN AMERICA: PHARMACOKINETICS/PHARMACODYNAMICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 82 MIDDLE EAST & AFRICA: PHARMACOKINETICS/PHARMACODYNAMICS MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.2.2 Toxicology testing
6.3.2.2.1 Growing need to provide high-quality and safe drugs to drive segment
TABLE 83 TOXICOLOGY TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 84 NORTH AMERICA: TOXICOLOGY TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 85 EUROPE: TOXICOLOGY TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 86 ASIA PACIFIC: TOXICOLOGY TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 87 LATIN AMERICA: TOXICOLOGY TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 88 MIDDLE EAST & AFRICA: TOXICOLOGY TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.2.3 Other preclinical services
TABLE 89 OTHER PRECLINICAL SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 90 NORTH AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 91 EUROPE: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 92 ASIA PACIFIC: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 93 LATIN AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 94 MIDDLE EAST & AFRICA: OTHER PRECLINICAL SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.3 DISCOVERY STUDIES
6.3.3.1 Increasing reliance on CRO services for target identification and validation to propel segment
TABLE 95 DISCOVERY STUDIES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 96 NORTH AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 97 EUROPE: DISCOVERY STUDIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 98 ASIA PACIFIC: DISCOVERY STUDIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 99 LATIN AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 100 MIDDLE EAST & AFRICA: DISCOVERY STUDIES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4 LABORATORY SERVICES
TABLE 101 EXAMPLES OF LABORATORY SERVICES OFFERED BY MARKET PLAYERS
TABLE 102 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 103 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR LABORATORY SERVICES, BY REGION, 2022–2029 (USD MILLION)
TABLE 104 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR LABORATORY SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 105 EUROPE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 106 ASIA PACIFIC: MARKET FOR LABORATORY SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 107 LATIN AMERICA: MARKET FOR LABORATORY SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 108 MIDDLE EAST & AFRICA: MARKET FOR LABORATORY SERVICES, BY REGION, 2022–2029 (USD MILLION)
6.4.1 ANALYTICAL TESTING
TABLE 109 ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 110 ANALYTICAL TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 111 NORTH AMERICA: ANALYTICAL TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 112 EUROPE: ANALYTICAL TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 113 ASIA PACIFIC: ANALYTICAL TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 114 LATIN AMERICA: ANALYTICAL TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 115 MIDDLE EAST & AFRICA: ANALYTICAL TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.1.1 Physical characterization
6.4.1.1.1 Growing need to reduce risk of product failures to drive segment
TABLE 116 PHYSICAL CHARACTERIZATION MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 117 NORTH AMERICA: PHYSICAL CHARACTERIZATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 118 EUROPE: PHYSICAL CHARACTERIZATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 119 ASIA PACIFIC: PHYSICAL CHARACTERIZATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 120 LATIN AMERICA: PHYSICAL CHARACTERIZATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 121 MIDDLE EAST & AFRICA: PHYSICAL CHARACTERIZATION MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.1.2 Raw material testing
6.4.1.2.1 Importance of quality and purity of raw materials to propel segment
TABLE 122 RAW MATERIAL TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 123 NORTH AMERICA: RAW MATERIAL TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 124 EUROPE: RAW MATERIAL TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 125 ASIA PACIFIC: RAW MATERIAL TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 126 LATIN AMERICA: RAW MATERIAL TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 127 MIDDLE EAST & AFRICA: RAW MATERIAL TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.1.3 Batch-release testing
6.4.1.3.1 Wide range of batch-release testing services offered by CROs to propel growth
TABLE 128 BATCH-RELEASE TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 129 NORTH AMERICA: BATCH-RELEASE TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 130 EUROPE: BATCH-RELEASE TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 131 ASIA PACIFIC: BATCH-RELEASE TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 132 LATIN AMERICA: BATCH-RELEASE TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 133 MIDDLE EAST & AFRICA: BATCH-RELEASE TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.1.4 Stability testing
6.4.1.4.1 Long-term quality, safety, and efficacy of pharmaceutical products to drive segment
TABLE 134 STABILITY TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 135 NORTH AMERICA: STABILITY TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 136 EUROPE: STABILITY TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 137 ASIA PACIFIC: STABILITY TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 138 LATIN AMERICA: STABILITY TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 139 MIDDLE EAST & AFRICA: STABILITY TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.1.5 Other analytical testing
TABLE 140 OTHER ANALYTICAL TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 141 NORTH AMERICA: OTHER ANALYTICAL TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 142 EUROPE: OTHER ANALYTICAL TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 143 ASIA PACIFIC: OTHER ANALYTICAL TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 144 LATIN AMERICA: OTHER ANALYTICAL TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 145 MIDDLE EAST & AFRICA: OTHER ANALYTICAL TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.2 BIOANALYTICAL TESTING
6.4.2.1 Rising significance of accurate PK/PD studies to drive segment
TABLE 146 BIOANALYTICAL TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 147 NORTH AMERICA: BIOANALYTICAL TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 148 EUROPE: BIOANALYTICAL TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 149 ASIA PACIFIC: BIOANALYTICAL TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 150 LATIN AMERICA: BIOANALYTICAL TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 151 MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
6.5 CONSULTING SERVICES
6.5.1 GROWING ADOPTION OF CONSULTING SERVICES FOR FASTER REGULATORY APPROVALS TO SUPPORT MARKET
TABLE 152 EXAMPLES OF CONSULTING SERVICES OFFERED BY MARKET PLAYERS
TABLE 153 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR CONSULTING SERVICES, BY REGION, 2022–2029 (USD MILLION)
TABLE 154 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR CONSULTING SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 155 EUROPE: CRO SERVICES MARKET FOR CONSULTING SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 156 ASIA PACIFIC: MARKET FOR CONSULTING SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 157 LATIN AMERICA: MARKET FOR CONSULTING SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 158 MIDDLE EAST & AFRICA: MARKET FOR CONSULTING SERVICES, BY REGION, 2022–2029 (USD MILLION)
6.6 DATA MANAGEMENT SERVICES
6.6.1 DATA MANAGEMENT SERVICES TO COMMAND HIGHEST GROWTH RATE DURING FORECAST PERIOD
TABLE 159 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY MARKET PLAYERS
TABLE 160 MARKET FOR DATA MANAGEMENT SERVICES, BY REGION, 2022–2029 (USD MILLION)
TABLE 161 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 162 EUROPE: MARKET FOR DATA MANAGEMENT SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 163 ASIA PACIFIC: MARKET FOR DATA MANAGEMENT SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 164 LATIN AMERICA: MARKET FOR DATA MANAGEMENT SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 165 MIDDLE EAST & AFRICA: MARKET FOR DATA MANAGEMENT SERVICES, BY REGION, 2022–2029 (USD MILLION)

7 CRO SERVICES MARKET, BY THERAPEUTIC AREA (Page No. - 194)
7.1 INTRODUCTION
TABLE 166 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
7.2 ONCOLOGY
TABLE 167 NUMBER OF NEW CANCER CASES, BY TYPE, 2020 VS. 2040
FIGURE 32 NUMBER OF REGISTERED ONCOLOGY CLINICAL TRIALS, 2012–2023 (THOUSAND)
TABLE 168 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY, 2023
TABLE 169 MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 170 MARKET FOR ONCOLOGY, BY REGION, 2022–2029 (USD MILLION)
TABLE 171 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 172 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 173 ASIA PACIFIC: MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 174 LATIN AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 175 MIDDLE EAST & AFRICA: MARKET FOR ONCOLOGY, BY REGION, 2022–2029 (USD MILLION)
7.2.1 BREAST CANCER
7.2.1.1 Strong R&D pipeline for breast cancer drugs to drive segment
TABLE 176 BREAST CANCER MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 177 NORTH AMERICA: BREAST CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 178 EUROPE: BREAST CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 179 ASIA PACIFIC: BREAST CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 180 LATIN AMERICA: BREAST CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 181 MIDDLE EAST & AFRICA: BREAST CANCER MARKET, BY REGION, 2022–2029 (USD MILLION)
7.2.2 LUNG CANCER
7.2.2.1 Increasing focus on research for advanced treatment to drive segment
TABLE 182 LUNG CANCER MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 183 NORTH AMERICA: LUNG CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 184 EUROPE: LUNG CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 185 ASIA PACIFIC: LUNG CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 186 LATIN AMERICA: LUNG CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 187 MIDDLE EAST & AFRICA: LUNG CANCER MARKET, BY REGION, 2022–2029 (USD MILLION)
7.2.3 PROSTATE CANCER
7.2.3.1 Rising number of research initiatives to propel market
TABLE 188 PROSTATE CANCER MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 189 NORTH AMERICA: PROSTATE CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 190 EUROPE: PROSTATE CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 191 ASIA PACIFIC: PROSTATE CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 192 LATIN AMERICA: PROSTATE CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 193 MIDDLE EAST & AFRICA: PROSTRATE CANCER MARKET, BY REGION, 2022–2029 (USD MILLION)
7.2.4 COLORECTAL CANCER
7.2.4.1 Increasing drug research activities to support market
TABLE 194 COLORECTAL CANCER MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 195 NORTH AMERICA: COLORECTAL CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 196 EUROPE: COLORECTAL CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 197 ASIA PACIFIC: COLORECTAL CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 198 LATIN AMERICA: COLORECTAL CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 199 MIDDLE EAST & AFRICA: COLORECTAL CANCER MARKET, BY REGION, 2022–2029 (USD MILLION)
7.2.5 OTHER CANCERS
TABLE 200 NUMBER OF DRUGS IN R&D PIPELINE FOR OTHER CANCERS, 2022 AND 2023
TABLE 201 OTHER CANCERS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 202 NORTH AMERICA: OTHER CANCERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 203 EUROPE: OTHER CANCERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 204 ASIA PACIFIC: OTHER CANCERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 205 LATIN AMERICA: OTHER CANCERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 206 MIDDLE EAST & AFRICA: OTHER CANCERS MARKET, BY REGION, 2022–2029 (USD MILLION)
7.3 INFECTIOUS DISEASES
7.3.1 GROWING INCIDENCE OF CHRONIC INFECTIONS TO SUPPORT MARKET
TABLE 207 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 208 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 209 EUROPE: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 210 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 211 LATIN AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 212 MIDDLE EAST & AFRICA: MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)
7.4 CARDIOVASCULAR SYSTEM DISORDERS
7.4.1 INCREASING PREVALENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
TABLE 213 EXAMPLES OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (AS OF DECEMBER 2023)
TABLE 214 CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 215 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 216 EUROPE: MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 217 ASIA PACIFIC: MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 218 LATIN AMERICA: MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 219 MIDDLE EAST & AFRICA: MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2022–2029 (USD MILLION)
7.5 NEUROLOGY
7.5.1 INCREASING INVESTMENTS IN R&D TO DRIVE MARKET
TABLE 220 CRO SERVICES MARKET FOR NEUROLOGY, BY REGION, 2022–2029 (USD MILLION)
TABLE 221 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 222 EUROPE: MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 223 ASIA PACIFIC: MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 224 LATIN AMERICA: MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 225 MIDDLE EAST & AFRICA: MARKET FOR NEUROLOGY, BY REGION, 2022–2029 (USD MILLION)
7.6 METABOLIC DISORDERS/ENDOCRINOLOGY
7.6.1 INCREASING NUMBER OF DIABETES PATIENTS TO BOOST MARKET
FIGURE 33 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION)
TABLE 226 CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2022–2029 (USD MILLION)
TABLE 227 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 228 EUROPE: MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 229 ASIA PACIFIC: MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 230 LATIN AMERICA: MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 231 MIDDLE EAST & AFRICA: MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2022–2029 (USD MILLION)
7.7 IMMUNOLOGICAL DISORDERS
7.7.1 GROWING CLINICAL RESEARCH AND RISING NUMBER OF DRUGS IN R&D PIPELINE TO DRIVE MARKET
TABLE 232 EXAMPLES OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS, 2023
TABLE 233 CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 234 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 235 EUROPE: MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 236 ASIA PACIFIC: MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 237 LATIN AMERICA: MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 238 MIDDLE EAST & AFRICA: MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION)
7.8 VACCINES
7.8.1 GROWING PREVALENCE OF INFECTIOUS DISEASES AND RISING GOVERNMENT FUNDING TO SUPPORT MARKET
TABLE 239 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR VACCINES, BY REGION, 2022–2029 (USD MILLION)
TABLE 240 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR VACCINES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 241 EUROPE: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 242 ASIA PACIFIC: MARKET FOR VACCINES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 243 LATIN AMERICA: MARKET FOR VACCINES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 244 MIDDLE EAST & AFRICA: MARKET FOR VACCINES, BY REGION, 2022–2029 (USD MILLION)
7.9 PSYCHIATRY
7.9.1 GROWING CASES OF PSYCHIATRIC DISORDERS AND INCREASING INVESTMENT IN R&D TO DRIVE MARKET
TABLE 245 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR PSYCHIATRY, BY REGION, 2022–2029 (USD MILLION)
TABLE 246 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 247 EUROPE: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 248 ASIA PACIFIC: MARKET FOR PSYCHIATRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 249 LATIN AMERICA: MARKET FOR PSYCHIATRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 250 MIDDLE EAST & AFRICA: MARKET FOR PSYCHIATRY, BY REGION, 2022–2029 (USD MILLION)
7.10 RESPIRATORY DISORDERS
7.10.1 RISING INCIDENCE OF UNDIAGNOSED RESPIRATORY DISORDERS AMONG CHILDREN TO PROPEL MARKET
TABLE 251 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES, 2023
TABLE 252 CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 253 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 254 EUROPE: MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 255 ASIA PACIFIC: MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 256 LATIN AMERICA: MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 257 MIDDLE EAST & AFRICA: MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2022–2029 (USD MILLION)
7.11 DERMATOLOGY
7.11.1 GROWING FOCUS ON DRUG DEVELOPMENT AGAINST VARIOUS SKIN CONDITIONS TO SUPPORT MARKET
TABLE 258 LIST OF PIPELINE DRUGS FOR SKIN DISEASES, 2023
TABLE 259 CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION, 2022–2029 (USD MILLION)
TABLE 260 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 261 EUROPE: MARKET FOR DERMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 262 ASIA PACIFIC: MARKET FOR DERMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 263 LATIN AMERICA: MARKET FOR DERMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 264 MIDDLE EAST & AFRICA: MARKET FOR DERMATOLOGY, BY REGION, 2022–2029 (USD MILLION)
7.12 OPHTHALMOLOGY
7.12.1 RISING NUMBER OF PIPELINE DRUGS AND GROWING FOCUS ON R&D TO DRIVE MARKET
TABLE 265 CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION, 2022–2029 (USD MILLION)
TABLE 266 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 267 EUROPE: MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 268 ASIA PACIFIC: MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 269 LATIN AMERICA: MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 270 MIDDLE EAST & AFRICA: MARKET FOR OPHTHALMOLOGY, BY REGION, 2022–2029 (USD MILLION)
7.13 GASTROINTESTINAL DISEASES
7.13.1 INCREASING LEVELS OF OBESITY WITH LIFESTYLE AND DIETARY CHANGES TO DRIVE MARKET
TABLE 271 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 272 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 273 EUROPE: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 274 ASIA PACIFIC: MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 275 LATIN AMERICA: MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 276 MIDDLE EAST & AFRICA: MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2022–2029 (USD MILLION)
7.14 GENITOURINARY & WOMEN’S HEALTH
7.14.1 RISING PREVALENCE OF CHRONIC DISORDERS AND INCREASING NUMBER OF PIPELINE DRUGS TO PROPEL MARKET
TABLE 277 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION, 2022–2029 (USD MILLION)
TABLE 278 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 279 EUROPE: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 280 ASIA PACIFIC: MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 281 LATIN AMERICA: MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 282 MIDDLE EAST & AFRICA: MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION, 2022–2029 (USD MILLION)
7.15 HEMATOLOGY
7.15.1 GROWING PREVALENCE OF BLOOD-RELATED DISEASES TO SUPPORT MARKET
TABLE 283 CRO SERVICES MARKET FOR HEMATOLOGY, BY REGION, 2022–2029 (USD MILLION)
TABLE 284 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 285 EUROPE: MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 286 ASIA PACIFIC: MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 287 LATIN AMERICA: MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 288 MIDDLE EAST & AFRICA: MARKET FOR HEMATOLOGY, BY REGION, 2022–2029 (USD MILLION)
7.16 OTHER THERAPEUTIC AREAS
TABLE 289 CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022–2029 (USD MILLION)
TABLE 290 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 291 EUROPE: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 292 ASIA PACIFIC: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 293 LATIN AMERICA: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 294 MIDDLE EAST & AFRICA: MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022–2029 (USD MILLION)
7.17 CUSTOMIZATION
7.17.1 CELL & GENE THERAPY
7.17.1.1 Growing investments for advanced research initiatives to support market
TABLE 295 CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY REGION, 2022–2029 (USD MILLION)
TABLE 296 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 297 EUROPE: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 298 ASIA PACIFIC: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 299 LATIN AMERICA: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 300 MIDDLE EAST & AFRICA: MARKET FOR CELL & GENE THERAPY, BY REGION, 2022–2029 (USD MILLION)
7.17.2 RARE DISEASES
7.17.2.1 Rising number of R&D activities for rare disease treatment to drive market
TABLE 301 CRO SERVICES MARKET FOR RARE DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 302 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 303 EUROPE: MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 304 ASIA PACIFIC: MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 305 LATIN AMERICA: MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 306 MIDDLE EAST & AFRICA: MARKET FOR RARE DISEASES, BY REGION, 2022–2029 (USD MILLION)
7.17.3 BIOSIMILARS
7.17.3.1 Growing focus on biosimilars and patent expiration of biologics to drive market
TABLE 307 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR BIOSIMILARS, BY REGION, 2022–2029 (USD MILLION)
TABLE 308 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 309 EUROPE: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 310 ASIA PACIFIC: MARKET FOR BIOSIMILARS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 311 LATIN AMERICA: MARKET FOR BIOSIMILARS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 312 MIDDLE EAST & AFRICA: MARKET FOR BIOSIMILARS, BY REGION, 2022–2029 (USD MILLION)
TABLE 313 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2022–2029 (USD MILLION)
7.17.3.2 Monoclonal antibodies
TABLE 314 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 315 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 316 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 317 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 318 LATIN AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 319 MIDDLE EAST & AFRICA: MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
7.17.3.3 Insulin
TABLE 320 INSULIN MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 321 NORTH AMERICA: INSULIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 322 EUROPE: INSULIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 323 ASIA PACIFIC: INSULIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 324 LATIN AMERICA: INSULIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 325 MIDDLE EAST & AFRICA: INSULIN MARKET, BY REGION, 2022–2029 (USD MILLION)
7.17.3.4 CSF
TABLE 326 CSF MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 327 NORTH AMERICA: CSF MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 328 EUROPE: CSF MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 329 ASIA PACIFIC: CSF MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 330 LATIN AMERICA: CSF MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 331 MIDDLE EAST & AFRICA: CSF MARKET, BY REGION, 2022–2029 (USD MILLION)
7.17.3.5 Erythropoietin
TABLE 332 ERYTHROPOIETIN MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 333 NORTH AMERICA: ERYTHROPOIETIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 334 EUROPE: ERYTHROPOIETIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 335 ASIA PACIFIC: ERYTHROPOIETIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 336 LATIN AMERICA: ERYTHROPOIETIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 337 MIDDLE EAST & AFRICA: ERYTHROPOIETIN MARKET, BY REGION, 2022–2029 (USD MILLION)
7.17.3.6 Other biosimilars
TABLE 338 OTHER BIOSIMILARS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 339 NORTH AMERICA: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 340 EUROPE: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 341 ASIA PACIFIC: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 342 LATIN AMERICA: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 343 MIDDLE EAST & AFRICA: OTHER BIOSIMILARS MARKET, BY REGION, 2022–2029 (USD MILLION)
8 CRO SERVICES MARKET, BY END USER (Page No. - 276)
8.1 INTRODUCTION
TABLE 344 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
8.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
8.2.1 STABLE R&D PIPELINES AND INCREASED INVESTMENTS TO DRIVE MARKET
FIGURE 34 ANNUAL DRUG APPROVALS, BY CDER (FDA), 2012–2023
FIGURE 35 R&D SPENDING OF PHARMACEUTICAL MEMBER COMPANIES, 2012–2022
TABLE 345 CRO SERVICES MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 346 NORTH AMERICA: MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 347 EUROPE: MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 348 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 349 LATIN AMERICA: MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 350 MIDDLE EAST & AFRICA: MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)
8.3 MEDICAL DEVICE COMPANIES
8.3.1 INCREASING NUMBER OF GROWTH INITIATIVES BY MEDTECH ORGANIZATIONS TO DRIVE MARKET
FIGURE 36 US FDA DE NOVO MEDICAL DEVICE APPROVALS (2012–2023)
TABLE 351 CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 352 NORTH AMERICA: MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 353 EUROPE: MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 354 ASIA PACIFIC: MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 355 LATIN AMERICA: MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 356 MIDDLE EAST & AFRICA: MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2022–2029 (USD MILLION)
8.4 ACADEMIC INSTITUTES
8.4.1 RISING NUMBER OF COLLABORATIONS BETWEEN CONTRACT RESEARCH ORGANIZATIONS AND ACADEMIA TO DRIVE MARKET
TABLE 357 CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
TABLE 358 NORTH AMERICA: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 359 EUROPE: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 360 ASIA PACIFIC: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 361 LATIN AMERICA: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 362 MIDDLE EAST & AFRICA: MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2022–2029 (USD MILLION)

9 CRO SERVICES MARKET, BY REGION (Page No. - 289)
9.1 INTRODUCTION
TABLE 363 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 37 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET SNAPSHOT
TABLE 364 NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 365 NORTH AMERICA: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 366 NORTH AMERICA: MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 367 NORTH AMERICA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 368 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 369 NORTH AMERICA: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 370 NORTH AMERICA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 371 NORTH AMERICA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 372 NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 373 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.2.1 NORTH AMERICA: RECESSION IMPACT
9.2.2 US
9.2.2.1 US to dominate North American CRO services market during forecast period
FIGURE 38 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (JANUARY 2022 VS. JANUARY 2023)
TABLE 374 US: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 375 US: MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 376 US: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 377 US: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 378 US: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 379 US: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 380 US: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 381 US: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 382 US: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.2.3 CANADA
9.2.3.1 Short approval time and favorable government R&D investments to drive market
TABLE 383 CANADA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 384 CANADA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 385 CANADA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 386 CANADA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 387 CANADA: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 388 CANADA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 389 CANADA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 390 CANADA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 391 CANADA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.3 EUROPE
TABLE 392 EUROPE: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 393 EUROPE: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 394 EUROPE: MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 395 EUROPE: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 396 EUROPE: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 397 EUROPE: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 398 EUROPE: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 399 EUROPE: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 400 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 401 EUROPE: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.3.1 EUROPE: RECESSION IMPACT
9.3.2 GERMANY
9.3.2.1 Growing R&D spending and favorable government policies to propel market
TABLE 402 GERMANY: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 403 GERMANY: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 404 GERMANY: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 405 GERMANY: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 406 GERMANY: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 407 GERMANY: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 408 GERMANY: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 409 GERMANY: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 410 GERMANY: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.3.3 UK
9.3.3.1 Growth in R&D expenditure in pharmaceutical industry to boost market
TABLE 411 UK: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 412 UK: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 413 UK: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 414 UK: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 415 UK: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 416 UK: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 417 UK: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 418 UK: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 419 UK: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.3.4 FRANCE
9.3.4.1 Government support for effective drug research to drive market growth
TABLE 420 FRANCE: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 421 FRANCE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 422 FRANCE: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 423 FRANCE: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 424 FRANCE: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 425 FRANCE: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 426 FRANCE: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 427 FRANCE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 428 FRANCE: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.3.5 ITALY
9.3.5.1 Increased availability of funding for drug discovery and development to drive market
TABLE 429 ITALY: NUMBER OF CLINICAL TRIALS IN ITALY, BY COMPANY (JANUARY 2022 VS. JANUARY 2023)
TABLE 430 ITALY: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 431 ITALY: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 432 ITALY: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 433 ITALY: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 434 ITALY: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 435 ITALY: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 436 ITALY: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 437 ITALY: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 438 ITALY: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.3.6 SPAIN
9.3.6.1 Growing R&D expenditure to boost market
TABLE 439 SPAIN: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 440 SPAIN: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 441 SPAIN: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 442 SPAIN: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 443 SPAIN: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 444 SPAIN: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 445 SPAIN: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 446 SPAIN: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 447 SPAIN: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.3.7 REST OF EUROPE
TABLE 448 REST OF EUROPE: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 449 REST OF EUROPE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 450 REST OF EUROPE: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 451 REST OF EUROPE: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 452 REST OF EUROPE: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 453 REST OF EUROPE: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 454 REST OF EUROPE: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 455 REST OF EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 456 REST OF EUROPE: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 39 ASIA PACIFIC: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET SNAPSHOT
TABLE 457 ASIA PACIFIC: CRO SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 458 ASIA PACIFIC: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 459 ASIA PACIFIC: MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 460 ASIA PACIFIC: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 461 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 462 ASIA PACIFIC: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 463 ASIA PACIFIC: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 464 ASIA PACIFIC: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 465 ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 466 ASIA PACIFIC: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.4.1 ASIA PACIFIC: RECESSION IMPACT
9.4.2 CHINA
9.4.2.1 Low manufacturing cost and increased establishment of R&D centers to drive market
TABLE 467 CHINA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 468 CHINA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 469 CHINA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 470 CHINA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 471 CHINA: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 472 CHINA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 473 CHINA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 474 CHINA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 475 CHINA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Growth in pharmaceutical industry and favorable scenario for foreign direct investment to propel market
TABLE 476 INDIA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 477 INDIA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 478 INDIA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 479 INDIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 480 INDIA: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 481 INDIA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 482 INDIA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 483 INDIA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 484 INDIA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.4.4 JAPAN
9.4.4.1 Decline in number of clinical trials to limit market
TABLE 485 JAPAN: TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA, 2020, 2022, AND 2023
TABLE 486 JAPAN: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 487 JAPAN: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 488 JAPAN: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 489 JAPAN: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 490 JAPAN: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 491 JAPAN: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 492 JAPAN: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 493 JAPAN: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 494 JAPAN: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.4.5 AUSTRALIA
9.4.5.1 Favorable tax incentives and cash rebates to pharmaceutical companies to support market
TABLE 495 AUSTRALIA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 496 AUSTRALIA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 497 AUSTRALIA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 498 AUSTRALIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 499 AUSTRALIA: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 500 AUSTRALIA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 501 AUSTRALIA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 502 AUSTRALIA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 503 AUSTRALIA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.4.6 SOUTH KOREA
9.4.6.1 Favorable government initiatives for drug development to drive market
TABLE 504 SOUTH KOREA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 505 SOUTH KOREA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 506 SOUTH KOREA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 507 SOUTH KOREA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 508 SOUTH KOREA: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 509 SOUTH KOREA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 510 SOUTH KOREA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 511 SOUTH KOREA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 512 SOUTH KOREA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.4.7 NEW ZEALAND
9.4.7.1 Rising number of key players and growing R&D activities to support market
TABLE 513 NEW ZEALAND: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 514 NEW ZEALAND: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 515 NEW ZEALAND: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 516 NEW ZEALAND: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 517 NEW ZEALAND: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 518 NEW ZEALAND: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 519 NEW ZEALAND: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 520 NEW ZEALAND: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 521 NEW ZEALAND: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.4.8 REST OF ASIA PACIFIC
TABLE 522 REST OF ASIA PACIFIC: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 523 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 524 REST OF ASIA PACIFIC: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 525 REST OF ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 526 REST OF ASIA PACIFIC: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 527 REST OF ASIA PACIFIC: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 528 REST OF ASIA PACIFIC: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 529 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 530 REST OF ASIA PACIFIC: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.5 LATIN AMERICA
TABLE 531 LATIN AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 532 LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 533 LATIN AMERICA: MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 534 LATIN AMERICA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 535 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 536 LATIN AMERICA: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 537 LATIN AMERICA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 538 LATIN AMERICA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 539 LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 540 LATIN AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.5.1 LATIN AMERICA: RECESSION IMPACT
9.5.2 BRAZIL
9.5.2.1 Increased government investments in pharmaceutical R&D to drive market
TABLE 541 BRAZIL: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 542 BRAZIL: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 543 BRAZIL: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 544 BRAZIL: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 545 BRAZIL: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 546 BRAZIL: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 547 BRAZIL: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 548 BRAZIL: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 549 BRAZIL: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.5.3 MEXICO
9.5.3.1 Favorable government policies for R&D and manufacturing to drive market
TABLE 550 MEXICO: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 551 MEXICO: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 552 MEXICO: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 553 MEXICO: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 554 MEXICO: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 555 MEXICO: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 556 MEXICO: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 557 MEXICO: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 558 MEXICO: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.5.4 REST OF LATIN AMERICA
TABLE 559 REST OF LATIN AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 560 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 561 REST OF LATIN AMERICA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 562 REST OF LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 563 REST OF LATIN AMERICA: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 564 REST OF LATIN AMERICA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 565 REST OF LATIN AMERICA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 566 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 567 REST OF LATIN AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
TABLE 568 MIDDLE EAST & AFRICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 569 MIDDLE EAST & AFRICA: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 570 MIDDLE EAST & AFRICA: MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 571 MIDDLE EAST & AFRICA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 572 MIDDLE EAST & AFRICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 573 MIDDLE EAST & AFRICA: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 574 MIDDLE EAST & AFRICA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 575 MIDDLE EAST & AFRICA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 576 MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 577 MIDDLE EAST & AFRICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
9.6.2 MIDDLE EAST
9.6.2.1 Increase in clinical research activities to drive market
TABLE 578 MIDDLE EAST: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 579 MIDDLE EAST: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 580 MIDDLE EAST: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 581 MIDDLE EAST: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 582 MIDDLE EAST: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 583 MIDDLE EAST: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 584 MIDDLE EAST: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 585 MIDDLE EAST: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 586 MIDDLE EAST: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.6.3 AFRICA
9.6.3.1 Growth in pharmaceutical industry to support market
TABLE 587 AFRICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 588 AFRICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
TABLE 589 AFRICA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 590 AFRICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 591 AFRICA: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 592 AFRICA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 593 AFRICA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 594 AFRICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 595 AFRICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(PH4672-24 )"医薬品開発業務受託機関(CRO)サービスの世界市場予測(~2029):種類別、治療領域別" (英文:Contract Research Organization (CROs) Services Market by Type (Early Phase, Clinical, Lab, Consulting, Data Management), Therapeutic Area (Cancer, Infectious Disease, Neurology, Dermatology, Immunology, Hematology, Vaccines, CGT) - Global Forecast to 2029)はMarketsandMarkets社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。